Summary
PTT-119, a new synthetic alkylating compound, has shown a marked “in vitro” inhibitory effect on chronic myeloid leukemia (CML) granulo-monocytic precursors (CFU-GM) at doses greater than 5µg/ml. Based on previous experiences of synergistic associations between alkylating drugs and biological modifiers, we tested the effects of low doses of PTT-119 (from 0.1 to 1µg/ml) in concert with alpha, gamma, or alpha + gamma interferons and compared to IFNs alone, in order to investigate an alternative choice for treatment of CML patients in chronic phase. Our results showed a significantly higher CFU-GM cloning inhibition after addition of 100 or 1,000 U/ml of alpha IFN to 0.1µg/ml PTT-119 (from 39.6% ± 26.6 SD to 80.7% ± 10 SD and 91.5% ± 8 SD, respectively), while gamma IFN resulted in only a slight increase in colony growth inhibition when compared to the drug used alone. The association of alpha plus gamma IFN coupled with PTT-119 treatment did not significantly improve the results observed after exposure of leukemic progenitors to PTT-119 and alpha IFN alone. We conclude that a combined treatment with PTT-119 and IFN is probably worth testing both for purging methods before autologous bone marrow transplantation and for in vivo administration in chronic myeloid leukemia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Berens ME, Saito T, Welander CE, Modest EJ (1987) Antitumor activity of new anthracycline analogues in combination with interferon alpha. Cancer Chemother Pharmacol 19: 301–307
Cazzola M, Carlo Stella C, Dezza L, Meloni F, Pedrazzoli P, Ascari E (1987) Synergistic inhibitory effects of human recombinant alpha and gamma interferons on the in vitro growth of hemopoietic progenitors from patients with myeloproliferative disorders. 4th International Symposium on therapy of acute leukemias. Roma, p 429
Gresser I, Maury C, Tovey M (1978) Efficacy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice. Eur J Cancer 14: 97–101
Lemoli RM, Visani G, Tosi P, Mazza P, Motta MR, Rizzi S, Zinzani PL, Poluzzi C, Gherlinzoni F, Tura S (1988) Effects of a new bifunctional alkylating agent (PTT-119) on in vitro growth of human cell lines and normal myeloid progenitors (CFU-GM). Haematologica 73: 195–200
Lemoli RM, Visani G, Tosi P, Verlicchi F, Mazza P, Testoni N, Zaccaria A, Tura S (1989) Antileukemic activity of a new alkylating agent (PTT-119) on in vitro colony growth of hemopoietic precursors (CFU-GM) in chronic myelogenous leukemia. Cancer J 2: 260–262
Mazza P, Gherlinzoni F, Tura S (1987) Phase II study with PTT-119 in lymphoid malignancies. Preliminary report. 15th International Congress of Chemotherapy, Istanbul, p 207
Namba M, Jamamoto S, Tanaka H, Kamamuri T, Nobuhara M, Kimoto T (1984) In vitro and in vivo studies on potentiation of cytotoxic effects on anticancer drugs, or cobalt-60 gamma rays by interferon on human neoplastic cells. Cancer 54: 2262–2267
Pannuti F, Coppi G, Borella F, Martoni A, Urbano L, Melotti B (1988) Pharmacokinetics of PTT-119 in man. Chemioterapia 7: 113–116
Rooth MS, Foon KA (1986) Alpha interferon in the treatment of hematologic malignancies. Am J Med 81: 871–882
Talpaz M, Kantarjan H, Mc Credie K, Trujillo J, Keating M, Gutterman J (1986) Haematologic remission and cytogenetic improvement introduced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 314: 1065–1069
Talpaz M, Mc Credie K, Kantarjan H, Trujillo J, Keating M, Gutterman J (1986) Chronic myelogenous leukemia: hematological remission with alpha interferon. Br J Hematol 64: 87–95
Tura S, Mazza P, Gherlinzoni F, Zinzani PL, Poletti G, Visani G, Lemoli RM, Bandini G, Cavo M, Galieni P, Tassi C, Zanchini R (1988) Phase II study with a new alkylating agent (PTT-119) in lymphoid malignancies. Haematologica 6: 509–512
Visani G, Delwel R, Touw I, Lowemberg B (1987) Membrane receptors for interleukin 2 on hematopoietic precursors in chronic myeloid leukemia. Blood 69: 1182–1187
Visani G, Russo D, Rizzi S, Motta MR, Lemoli RM, Poluzzi C, Fanin R, Zuffa E, Tosi P, Baccarani M, Tura S (1988) Sensitivity of Phl+ CFU-GM to human interferon alpha and gamma alone and in combination. Blut 57: 41–44
Yagi MJ, Bekesi JG, Daniel MD, Holland JF, De Barbieri A (1984) Increased cancericidal activity of PTT-119, a new synthetic bis-(2-chloroethyl) amino-L-phenylalanine derivative with carrier amino acids. In vitro bioassay. Cancer Chemother Pharmacol 12: 70–76
Yagi MJ, Chin SE, Scanlon KJ, Holland JF, Beckesi JG (1985) PTT-119, p-F-Phe-m-bis-(2-chloroethyl) amino-L-Phe-Met etoxy HCL. A new chemotherapeutic agent active against drug resistant tumor cell lines. Biochem Pharmacol 34: 2347–2354
Yagi MJ, Zanjani M, Holland JF, Bekesi JG (1984) Increased cancericidal activity of PTT-119, a new synthetic bis-(2-chloroethyl) amino-L-phenylalanine derivative with carrier amino acids. In vivo bioassay. Cancer Chemother Pharmacol 12: 77–82
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Visani, G., Lemoli, R.M., Tosi, P. et al. Sensitivity of chronic myeloid leukemia hemopoietic progenitors to PTT-119 in combination with human recombinant interferon alpha and gamma. Blut 60, 287–290 (1990). https://doi.org/10.1007/BF01736230
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01736230